All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Matthias Holdhoff, Johns Hopkins University, discusses the treatment options for elderly patients with primary central nervous system (CNS) lymphoma.
Dr. Holdhoff explains how over 50% of patients who are diagnosed are 60 years or older. The outcomes for patients who are treated for primary central nervous lymphomas has significantly improved over the last 4 decades, partly due to more aggressive therapies that have been tolerated reasonably well. Dr. Holdhoff then goes on to explain how the term elderly has evolved over time, as patients tend to live longer and comorbidities can be better managed, as well as how giving therapy with high dose methotrexate can very well be tolerated in old or very old patients.
What should be done for elderly patients with primary central nervous system lymphoma?
Chemotherapy-free approaches for indolent NHL and MCL
This month we will take a closer look at chemotherapy-free treatment strategies for iNHL and MCL. First, let's recap on some of the relevant material that we covered earlier this year.
ASCO 2019 | Smart Start phase 2 trial: Rituximab, lenalidomide & ibrutinib combination for naïve DLBCL
This phase II study investigated the efficacy of rituximab, lenalidomide, and ibrutinib combination prior to standard chemotherapy treatment, in...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox